references
ADVOCACY, COMMUNICATIONS & FUNDRAISING
SELECTED SCIENTIFIC ARTICLES AND PRESS COVERAGE
Special Issue: Novel therapeutic approaches for neglected infectious diseases Editorial: Novel Therapeutic Approaches for Neglected Infectious Diseases by Martin-Plaza J and Chatelain E. Journal of Biomolecular Screening, January 2015 Novel 3-nitrotriazole-based amides and carbinols as bifunctional antichagasic agents by Papadopoulou MV, Bloomer WD, Lepesheva GI, Rosenzweig HS, Kaiser M, Aguilera-Venegas B, Wilkinson SR, Chatelain E, Ioset JR. Journal of Medicinal Chemistry, January 2015 Repurposing of the Open Access Malaria Box for kinetoplastid diseases identifies novel active scaffolds against trypanosomatids by Kaiser M, Maes L, Tadoori LP, Spangenberg T, Ioset JR. Journal of Biomolecular Screening, February 2015 How can we end paediatric HIV? by Celletti F, Cohen J, Connor C, Lallemant M, Lee J. The Lancet HIV, March 2015 Enantiomers of nifurtimox do not exhibit stereoselective anti-T. cruzi activity, toxicity or pharmacokinetic properties by Moraes CB, White KL, Braillard S, Perez C, Goo J, Gaspar L, Shackleford DM, Cordeiro-da-Silva A, Thompson RC, Freitas-Junior L, Charman SA, Chatelain E. Antimicrobial Agents Chemotherapy, April 2015 Infectious diseases: Overcoming neglect of kinetoplastid diseases by Bilbe G. Science, May 2015 Translational challenges of animal models in Chagas disease drug development: A review by Chatelain E and Konar N. Drug Design, Development and Therapy, August 2015 Development and validation of a novel Leishmania donovani screening cascade for high-throughput screening using a novel axenic assay with high predictivity of leishmanicidal intracellular activity by Nühs A, De Rycker M, Manthri S, Comer E, Scherer CA, Schreiber SL, Ioset JR, Gray DW. PLOS Neglected Tropical Diseases, September 2015 Hit and lead criteria in drug discovery for infectious diseases of the developing world by Katsuno K, Burrows JN, Duncan K, Hooft van Huijsduijnen R, Kaneko T, Kita K, Mowbray CE, Schmatz D, Warner P, and Slingsby BT. Nature Reviews Drug Discovery, October 2015 Novel amino-pyrazole ureas with potent in vitro and in vivo antileishmanial activity by Mowbray C, Braillard S, Speed W, Glossop P, Whitlock G, Gibson K, Mills J, Brown A, Gardner JM, Cao Y, Hua W, Morgans G, Feijens P-B, Matheeussen A, Maes L . Journal of Medicinal Chemistry, November 2015
Chagas: An Emer ging Infectious g Disease Threat In U.S.
1 OCTOBER 2015
rch nd for obal research fu Experts call for gl d diseases d other neglecte tibiotics, Ebola an an 11 MAY 2015
La Argentina es el país con más infectados por el parásito del Cha
gas
20 APRIL 2015
More ne ed treat kal s to be done to la-azar
2 0 NOV EMBER 2015
Finding a Cure for Kala A ar Azar
31 JULY 2015
onomista e Eric Stobbaerts, ec ão doenças ‘S cientista político: o... cr velhas, não dão lu
8 APRIL 2015
h al Healt ld Glob ma he Unto T yceto 015 2015: M MBER 2 Story of 8 D EC E
Attack Japanese Companies Neglected Diseases
1 JUNE 2015
DNDi and Ta keda Collabo rate for the Le Optimization ad for Aminopyr azole Series fo Visceral Leish r maniasis
27 JULY 20 15
rt in bringing anies take pa “Japanese comp ents for the disease treatm s new infectiou public and an innovative poor through private fund” 4 JUNE 2015
“DNDi and Eisai entered into a join t development agreement with the aim to develop a cur e for mycetoma”
10 SEPTEMBER 2015
DNDi Annual Report 2015 › 65
